한글목차

살로그리타자르 마그네슘은 미국에서 시험 중의 분자로, 다낭성 난소 증후군(PCOS)을 수반하는 NAFLD, NASH,(PBC) 등의 간질환의 치료제로서 임상 평가 중입니다. 마그네슘은 PPAR 알파 및 PPAR 감마에 관여하는 독특한 메커니즘으로 지방증, 풍선 형성, 염증 및 섬유화를 포함한 NASH의 모든 구성 요소에 좋은 영향을 미칩니다는 것이 입증되었습니다.

2021년 5월, Zydus Therapeutics Inc.는 NASH 및 섬유증을 적응증으로 하는 대상자의 효능과 안전성을 평가하기 위한 2상 임상시험(EVIDENCES-X 시험)을 개시하는 승인을 미국 FDA에서 얻었습니다.

이 보고서는 주요 7개국에서 살로그리타자르 마그네슘 시장을 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 비알코올성 지방간염(NASH)에 있어서의 사로그리타자르, 마그네슘의 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 살로그리타자르 마그네슘 시장 평가

• 비알코올성 지방간염(NASH)에 있어서의 사로그리타자르, 마그네슘 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"Saroglitazar Magnesium Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Saroglitazar Magnesium for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Saroglitazar Magnesium for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Saroglitazar Magnesium for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Saroglitazar Magnesium market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Saroglitazar Magnesium is an investigational molecule in the US, undergoing clinical evaluation to treat liver diseases like NAFLD with polycystic ovary syndrome (PCOS), NASH, and (PBC). Non-clinical studies have demonstrated that Saroglitazar Magnesium, due to its unique mechanism of engaging PPAR alpha and PPAR gamma, favorably affects all components of NASH, including steatosis, ballooning, inflammation, and fibrosis.

In May 2021, Zydus Therapeutics Inc. received approval from the US FDA to initiate Phase II clinical trials, viz EVIDENCES-X trials of the molecule to evaluate its efficacy and safety in subjects with NASH and fibrosis indications.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Saroglitazar Magnesium description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Saroglitazar Magnesium regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Saroglitazar Magnesium research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Saroglitazar Magnesium.
• The report contains forecasted sales of Saroglitazar Magnesium for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Saroglitazar Magnesium in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Saroglitazar Magnesium Analytical Perspective by DelveInsight

• In-depth Saroglitazar Magnesium Market Assessment

This report provides a detailed market assessment of Saroglitazar Magnesium for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Saroglitazar Magnesium Clinical Assessment

The report provides the clinical trials information of Saroglitazar Magnesium for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Saroglitazar Magnesium dominance.
• Other emerging products for NASH are expected to give tough market competition to Saroglitazar Magnesium and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Saroglitazar Magnesium in NASH.
• Our in-depth analysis of the forecasted sales data of Saroglitazar Magnesium from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Saroglitazar Magnesium in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Saroglitazar Magnesium?
• What is the clinical trial status of the study related to Saroglitazar Magnesium in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Saroglitazar Magnesium development?
• What are the key designations that have been granted to Saroglitazar Magnesium for NASH?
• What is the forecasted market scenario of Saroglitazar Magnesium for NASH?
• What are the forecasted sales of Saroglitazar Magnesium in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Saroglitazar Magnesium for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Saroglitazar Magnesium Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Saroglitazar Magnesium Market Assessment

• 5.1. Market Outlook of Saroglitazar Magnesium in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Saroglitazar Magnesium in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Saroglitazar Magnesium in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Saroglitazar Magnesium in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Saroglitazar Magnesium in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Saroglitazar Magnesium in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Saroglitazar Magnesium in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Saroglitazar Magnesium in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Saroglitazar Magnesium in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options